arrow_back Back

CleanCap® AU saRNA CleanScript™ IVT Kit

SKU: K-7114
PREORDER before the 03-Aug-2026 launch and receive a complimentary 100 µg of a catalog saRNA of your choice (options below). After you order, the TriLink team will follow up to confirm your selection. Limit one free saRNA per order. Offer limited to the first 25 kits.
  1. CleanCap® AU EGFP saRNA (5mC), SKU: L-7901-100
  2. CleanCap® AU FLuc saRNA (5mC), SKU: L-7902-100

Description

TriLink’s CleanCap® AU saRNA CleanScript™ IVT Kit provides essential components for self-amplifying RNA (saRNA) or self-replicating RNA (srRNA) synthesis using co-transcriptional capping by in vitro transcription (IVT). The kit components are sufficient to run 20 × 20 µL reactions following our recommended IVT protocol. It includes a cap analog, modified and unmodified nucleotides, IVT enzymes, a reaction buffer, and a control DNA template. Each 20 µL reaction is expected to yield up to 150–190 µg of capped saRNA (up to 7.5–9.5 mg/mL, crude yield following LiCl purification) — approximately 3.0–3.8 mg per 20-reaction kit (K-7114-20).

As the first and only dedicated saRNA IVT kit, it is designed for cumulative gains in yield, quality, and expression. Key benefits include:

  • Time and cost savings — Co-transcriptional capping protocol with all necessary reagents for a single-tube reaction providing high yield, fewer steps, and less handling.
  • High capping efficiency — Protocol with CleanCap® AU cap analog to produce an optimal cap 1 with over 95% capping efficiency.
  • Increased saRNA yield — Buffer and kit components formulated using TriLink’s proprietary CleanScript® IVT method to yield up to 150–190 µg capped saRNA per 20 µL reaction from 2.4 µg linear plasmid.
  • Ultra-low double-stranded RNA (dsRNA) — Up to 85% dsRNA reduction (depending on modifications) using CleanScribe™ RNA Polymerase in place of wild-type T7 RNA polymerase in combination with the CleanScript IVT method.
  • Enhanced saRNA performance — Robust protein expression and low inflammatory responses from saRNA synthesized with CleanCap AU, CleanScribe RNA polymerase, and 5-methylcytidine (5mC).


The kit contains sufficient quantities of the following components to support 20 × 20 µL reactions:

  • CleanCap® Reagent AU
  • Adenosine-5′-Triphosphate (ATP)
  • Cytidine-5′-Triphosphate (CTP)
  • Guanosine-5′-Triphosphate (GTP)
  • Uridine-5′-Triphosphate (UTP)
  • 5-Methylcytidine-5′-Triphosphate (5mC)
  • AU CleanScribe™ RNA Polymerase Mix
  • 10X AU CleanScript™ IVT Buffer
  • saRNA FLuc Control DNA Template (linearized)

Important note:

  • This kit is specifically formulated and optimized for in vitro saRNA synthesis with CleanCap® AU capping. It is not optimal for standard mRNA synthesis or use with other cap analogs.
  • Users must design and source their own IVT template. PCR templates have not been validated for saRNA (see FAQ); use a fully linearized plasmid. Refer to the protocol’s[PK2.1] template design section or contact [email protected].

Product details
Catalog No K-7114
Recommended Storage -15 to -20 °C
Application In vitro transcription; co-transcriptional capping; self-amplifying RNA (saRNA / srRNA) synthesis
Cap AU Start, Cap 1, CleanCap AU
Cap Analogs CleanCap AU
Reaction Size 20 × 20 µL
Incubation 31 °C, 5 hours

Technical documents

Product FAQs

CleanCap AU preserves the authentic 5′ alphavirus end required for saRNA replication and provides an optimal Cap 1 structure with over 95% capping efficiency. AU-start saRNA templates require CleanCap AU; caps used for mRNA (e.g., AG or GG) are not suitable.

TriLink’s proprietary in vitro transcription method to produce high-quality, high-yield RNA while minimizing dsRNA. The kit’s reaction buffer is formulated on the CleanScript method and further optimized for long saRNA templates.

A novel enzyme that substitutes wild-type T7 RNA polymerase in IVT and reduces dsRNA formation by up to 85%. The AU CleanScribe™ RNA Polymerase Mix also contains RNase inhibitor and inorganic pyrophosphatase.

The kit provides all necessary reagents sufficient for 20 × 20 µL reactions (K-7114-20).

A typical AU CleanScript™ IVT reaction yields 150–190 µg of saRNA per 20 µL reaction (up to 7.5–9.5 mg/mL, crude following LiCl purification) using unmodified NTPs or 5mC.

The template must contain the correct T7 promoter sequence (5′ TAATACGACTCACTATA 3′) followed by an initiating sequence of 5′ ATG 3′ (recommended) or 5′ ATA 3′ for proper use with CleanCap AU.

The reaction conditions have been tested with templates up to ~18 kb, resulting in ~16 kb saRNA transcripts.

No, the plasmid DNA must be fully linearized. Residual circular plasmid will produce unwanted extended RNA byproducts that can affect your results.

Yes, PCR products can be used directly, though using silica-membrane-purified PCR products typically gives better results. Please ensure it contains the correct T7 promoter sequence and the start site as described in the template design section. The final concentration should be 0.025 ug/uL for PCR templates (compared to 0.05 ug/uL for plasmid templates).

A 5-hour incubation at 31 °C, using a thermal cycler with a heated lid or a dry-air incubator. The 31 °C temperature is optimized to promote saRNA integrity.

Yes. 5mC can be used in place of CTP to potentially suppress the interferon response and increase potency; replace CTP with the same concentration of 5mC.

DNase treatment is optional but recommended to remove template DNA. Use the one-pot DNase protocol in the manual or purify then DNase-treat.

Lithium chloride precipitation, spin columns (e.g., QIAGEN RNeasy), or oligo(dT). Oligo(dT) can yield higher-integrity saRNA but may be less efficient for VEE saRNA and require optimization.

To verify saRNA transcription and aid troubleshooting. Following the recommended protocol it yields 150–190 µg of 9.4 kb saRNA per 20 µL reaction. 12 µg of linearized control template (sufficient for 5 × 20 µL reactions; 26A poly(A) tail) is provided.

Yes, by adjusting the component amounts proportionally.

Certificate of analysis

Intellectual property

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

CleanCap capping technology

For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patents and patent pending, see trilinkbiotech.com/legal-notices.

  • CleanCap® AU saRNA CleanScript™ IVT Kit, 20 x 20 µL rxns (PREORDER) (sold as Each)
    SKU: K-7114-20
    $848.00
support Contact us home Return to TriLink homepage